Pages that link to "Item:Q4967095"
From MaRDI portal
The following pages link to Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents (Q4967095):
Displaying 10 items.
- Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control (Q454783) (← links)
- A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate (Q1733138) (← links)
- Adaptive oncology Phase I trial design of drug combinations with drug-drug interaction modeling (Q1782097) (← links)
- A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents (Q3064270) (← links)
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
- Flexible use of copula‐type model for dose‐finding in drug combination clinical trials (Q6055718) (← links)
- A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages (Q6572291) (← links)
- Bayesian dose escalation with overdose and underdose control utilizing all toxicities in phase I/II clinical trials (Q6625365) (← links)
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials (Q6626759) (← links)
- Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials (Q6637076) (← links)
